Get started
Author

Hilde Williams

Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial
2013 · Jeffrey Cummings, Stuart Isaacson, et al. · The Lancet · 966
On the Discovery and Development of Pimavanserin: A Novel Drug Candidate for Parkinson’s Psychosis
2014 · Uli Hacksell, Ethan S. Burstein, et al. · Neurochemical Research · 305
PDF
Pimavanserin, a Serotonin2A Receptor Inverse Agonist, for the Treatment of Parkinson's Disease Psychosis
2009 · Herbert Y Meltzer, Roger Mills, et al. · Neuropsychopharmacology · 294
PDF
Performance of a shortened Scale for Assessment of Positive Symptoms for Parkinson's disease psychosis
2012 · Tiffini Voss, Daun Bahr, et al. · Parkinsonism & Related Disorders · 87
The Inhibitory Effect of Interleukin-10 on Mouse Osteoclast Formation Involves Novel Tyrosine-Phosphorylated Proteins
2000 · Mei Hua Hong, Hilde Williams, et al. · Journal of Bone and Mineral Research · 77
Psychosis in Alzheimer’s Disease
2020 · Clive Ballard, Helen C. Kales, et al. · Current Neurology and Neuroscience Reports · 63
PDF
Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis
2015 · Clive Ballard, Stuart Isaacson, et al. · Journal of the American Medical Directors Association · 58
An Exploratory, Randomized, Double‐Blind Clinical Trial of Dipraglurant for Blepharospasm
2024 · Gamze Kilic‐Berkmen, Hodam Kim, et al. · Movement Disorders · 9
PDF
Long-term effectiveness of NUPLAZID™ (pimavanserin) in PD psychosis: Data from 2 open-label studies
2015 · Roger Mills, Stuart Isaacson, et al. · Parkinsonism & Related Disorders · 6
Efficacy and tolerability of NUPLAZID™ (pimavanserin) in PD Psychosis: Analysis of an integrated Phase 3 placebo-controlled dataset
2015 · Roger Mills, Joseph Friedman, et al. · Parkinsonism & Related Disorders · 3
Long-term effectiveness of NUPLAZID™ (pimavanserin) in PD psychosis: Data from 2 open-label studies
2015 · Roger Mills, Stuart Isaacson, et al. · Parkinsonism & Related Disorders · 3
O4–05–04: Antipsychotic efficacy and good tolerability in a Phase III placebo‐controlled study of pimavanserin in patients with Parkinson's disease psychosis (ACP‐103–020)
2013 · Clive Ballard, Roger Mills, et al. · Alzheimer s & Dementia · 1
Clinical Progress Update From PRO-101, a Hybrid Phase One Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Prosetin in Participants With ALS (P10-9.007)
2026 · Erin Fleming, Kristiana Salmon, et al. · Neurology
Impact of current antipsychotic medications on comparative mortality and adverse events in people with Parkinson’s disease psychosis (PDP)
2015 · Roger Mills, Clive Ballard, et al. · Parkinsonism & Related Disorders
Decreased burden among caregivers of patients with Parkinson’s disease psychosis (PDP) treated with pimavanserin, a selective 5-HT2A inverse agonist (P6.044)
2015 · Dag Aarsland, Roger Mills, et al. · Neurology
P3‐097: Improved nighttime sleep without increased daytime sedation in patients with Parkinson's disease psychosis treated with pimavanserin, a selective 5‐HT2A antagonist
2010 · Hilde Williams, Daun Bahr, et al. · Alzheimer s & Dementia
P3‐140: Decreased caregiver burden among carers of patients with Parkinson's disease psychosis treated with pimavanserin, a selective 5‐HT2A antagonist
2010 · Hilde Williams, Daun Bahr, et al. · Alzheimer s & Dementia
Pimavanserin - a potential first line therapy for Parkinson's disease psychosis
2009 · Uli Hacksell, Krista McFarland, et al.
Works count: 19
Citation count: 1,872
H-index: 8
I10-index: 7
Year
Topic
Type